Background: To evaluate the effectiveness and tolerability of the long-term treatment bone metastases with pamidronate in older patients. Materials and Methods: Twenty-two ambulatory patients aged 70 or older were included in the study. The median age was 73 (range 70–77). Ten patients (46%) were affected by breast carcinoma, 7 (32%) by prostate carcinoma and 5 (22%) by multiple myeloma. Nine (40%) patients presented co-morbidity. All of the patients presented at least one metastatic lytic bone lesion measuring 1 cm or more in diameter; the median lesion number was 2 (range 1–4). Hormonal therapy or chemotherapy regimen, were allowed as clinically required. Patients were treated with a fixed dose of sodium pamidronate, 90 mg in 3 h infusion every 4 weeks. Results: Partial response was shown in 6 (28%) patients, stable disease in 11 (50%), and progression (PD) in 5 (22%). 2 out of 5 patients with PD presented skeletal-related events (SREs) such as bone fracture. The median treatment duration was 19 months. The treatment was well tolerated; in 5 patients (23%) a GI fever was observed, in 3 patients (18%) G1 nausea, and in 3 patients (14) G1 diarrhea. Two cases (9%) of acute renal insufficiency (creatinine 1.7 and 1.6 mg/dl), and 3 cases (14%) of hypocalcemia (7.6, 7.5 and 7.8 mg/dl) were also registered. The renal dysfunction was reversible and without consequence. Conclusion: Our experience suggests that the bisphosphonates long-term administration is useful and did not cause significant side effects in elderly subjects. Low-grade pyrexia, nausea/vomiting, acute/reversible renal dysfunction and hypo-calcemia were the most frequent side effects reported. However, they were of low grade and in most cases, did not require dose modifications and/or hospitalization.

Mundy GR: Mechanism of osteolytic bone destruction. Bone 1991;12(suppl 1):51–56.
Hazard WR, Bierman El, Balss JP, et al: Principles of Geriatric Medicine and Gerontology, ed 4. New York, McGraw-Hill, 1999, pp 1560–1570.
Scher HI, Yogoda A: Bone metastases: Pathogenesis, treatment, and rationale for use of resorption inhibitors. Am J Med 1987;82(suppl A):6–28.
Fleisch H: Diphosphonates. Calcif Tissue Int 1997;27:91–94.
Jung A, Bisaz S, Fleisch H: The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973;11:69–280.
Dodwell DJ: Malignant bone resorption: Cellular and biochemical mechanisms. Ann Oncol 1992;3:257–267.
Fleisch H: Biphosphonates – history and experimental basis. Bone 1987;8(suppl 1):523–528.
Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML: Two modes of action of biphosphonates on osteoclastic resorption of mineralized matrix. Bone Mineral 1986;1:27–39.
Fleisch H: Biphosphonates in Bone Disease – from the Laboratory to the Patient, ed 2. Canforth, Parthenon, 1995, pp 38–56.
Gucalp R, Ritch P, Wiermich PH, Sarma PR, Keller A, Richman SP, et al: Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992:10:134–142.
Hortobagyi GN, Theriault RL, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785–1791.
Nussbaum SR, Younger J, et al: Single-dose intravenous therapy with pamidronate fort he treatment of hypercalcemia of malignancy. Am J Med 1993;95:297–304.
Daley-Yates PD, Dowell DJ, Pongchaidecha M, et al: The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 1991;49:433–435.
Body JJ: Clinical research up-date-zoledronate. Cancer 1997;80(suppl 8):1699–1701.
Powles T, Paterson S, Kaus JA, et al: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer, J Clin Oncol 2002;20:3219–3224.
Berenson JR, Hillner BE, Kyle RA, et al: American Society of Clinical oncology Clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719–3736.
Hillner BE, Ingle JN, Berenson JR, et al: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 2000;18:1378–1391.
Green JR: Antitumor effects of bisphosphonates. Cancer 2003;97(3 suppl):840–845.
Hamermann D: Toward an understanding of frailty. Ann Intern Med 1999;130:945–995.
Body JJ: Metastatic bone disease: Clinical and therapeutic aspects. Bone 1992;13(suppl 1):S57–S62.
McCloskey EV, Spector TD, Eyres KS, et al: The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 1993;3:138–147.
Cancer Facts and Figures 2001, vol 2001.Atlanta, America Cancer Society, 2001.
Yancik RM, Ries L: Cancer and older persons: A magnitude of the problem. Cancer 1994;74:1995–2003.
Samer J, Hunt WE, Key C, et al: Choice of cancer therapy varies with age of patient. JAMA 1986;255:3385–3390.
Greenfield J, Blanco DM, Elashoff RM, et al: Patterns of care related to age of breast cancer patients. JAMA 1987;20:2766–2770.
Stanta Y, Campagner L, Cavalieri F, et al: Cancer of the oldest old: what we have learned from autopsy studies. Clin Geriatr Med 1997;13:55–68.
Repetto L, Venturino A, Vercelli M, et al: Performance Status and comorbidity in elderly cancer patients compared with young patients with neoplastic and elderly patients without neoplastic conditions. Cancer 1998;82:760–765.
Kemeny M, Muss HB, Kornblith AB, et al: Barriers to participation of older women with breast cancer in clinical trials. Proc 36th Ann Meet Am Soc Clin Oncol, New Orleans, May 20–23, 2000.
Mahoney T, Kuo YH, Topilow A, et al: Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients? Ann Surg 2000;135:182–185.
Rose C, Ford J, et al: Pamidronate disodium (AREDIA), dose effect and tolerability evaluation in breast cancer patients with bone metastases. Ann Oncol 1992;3(suppl 5):85.
Morton AR, Cantrill JA, et al: Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonates (APD) in patients with breast cancer. BMJ 1988;297:72.
Clarke NW, Holbrook IB, et al: Osteoclast inhibition by pamidronate in metastatici prostate cancer: A preliminary study. Br J Cancer 1991;63:420.
Lahtinen R, Laakso M, et al: For the Finnish Leukaemia Group: Randomised, placebo-controlled multicentre trials of clodronate in multiple myeloma. Lancet 1992;340:1049.
Colemar RE: Skeletal complications of malignancy, Cancer 1997;80(suppl):1588–1594.
Francis MD, Martodam RR: Chemical, biochemical and medicinal properties of the diphosphonates; in Hilderbrand RL (ed): The Role of Phosphonates in Living Systems. Boca Raton, CRC Press, 1983.
Fleisch H: Bisphosphonates: mechanisms of action and clinical applications; in Peck WA (ed): Bone and Mineral Research. Excerpta Medica, Amsterdam, 1983, vol 1, p 319.
Theroault RL, Lipton A, Hortobagyi GN, et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. J Clin Oncol 1999;17:846–854.
Berenson JR, Lichtenstein AM, Porter L, et al: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593–602.
Lahtinen R, Laakso M, Palva I, et al: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340:1049–1052.
McCloskey EV, McLennan ICM, Drayson MT, et al: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998;100:317–325.
Coleman RE: Biochemical markers of malignant bone disease; in Rubens RD, Mundy GR (eds): Cancer and the Skeleton. London, Martin Dunitz, 2000, pp 137–150.
Vinholes JJF, Purohit OP, Abbey ME, et al: Relationships between biochemical and symptomatic response in a double-bind randomized trial of pamidronate for metastatic bone disease. Ann Oncol 1997;8:1243–1250.
Markowtiz Gs, Appel GB, Fine Pl, et al: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate, J Am Soc Nephrol 2001;12:1164–1172.
Bounameaux HM, Schifferli J, Montani JP, et al: Renal failure associated with intravenous bisphosphonate. Lancet 1993;i:471–473.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.